- Home
- SKWD vs ZYME Comparison
SKWD vs ZYME Comparison
Compare SKWD & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKWD | ZYME |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | SKWD | ZYME |
|---|---|---|
| Price | $48.57 | $25.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $64.80 | $36.33 |
| AVG Volume (30 Days) | ★ 538.2K | 513.9K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.81 | 33.33 |
| EPS | ★ 4.07 | N/A |
| Revenue | ★ $1,416,541,000.00 | $105,965,000.00 |
| Revenue This Year | $31.66 | $142.72 |
| Revenue Next Year | $13.67 | N/A |
| P/E Ratio | $11.87 | ★ N/A |
| Revenue Growth | 23.16 | ★ 38.87 |
| 52 Week Low | $42.45 | $9.03 |
| 52 Week High | $65.05 | $28.49 |
Technical Indicators
Market Signals| Indicator | SKWD | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 59.46 | 63.03 |
| Support Level | $43.94 | $24.79 |
| Resistance Level | $50.44 | $27.19 |
| Average True Range (ATR) | 1.83 | 0.98 |
| MACD | 0.42 | 0.25 |
| Stochastic Oscillator | 90.42 | 88.55 |
Price Performance
Historical ComparisonAbout SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.